drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (autologous CAR T cells)
drug_description
Autologous, gene-modified CAR T-cell therapy engineered to express chimeric antigen receptors targeting CD19 and CD22; administered as a single IV infusion. CAR engagement triggers CD3zeta/co-stimulatory signaling leading to T-cell activation, expansion, cytokine release, and cytotoxic killing of malignant B-lineage lymphoblasts. Manufactured via the T-Charge process.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are gene-modified to express chimeric antigen receptors targeting CD19 and CD22. Upon antigen engagement, CAR-mediated CD3ζ and co‑stimulatory signaling activates and expands the T cells, driving cytokine release and cytotoxic killing of CD19/CD22‑positive malignant B‑lineage lymphoblasts.
drug_name
IMJ995
nct_id_drug_ref
NCT05168748